tiprankstipranks
Trending News
More News >

Immucell Elects Directors, Rejects Compensation Proposals

Story Highlights
Immucell Elects Directors, Rejects Compensation Proposals

Don’t Miss TipRanks’ Half-Year Sale

Immucell ( (ICCC) ) has shared an announcement.

Immucell held its 2025 Annual Meeting of Stockholders on June 12, 2025, via remote communication. During the meeting, all seven director nominees were elected, but the proposals to approve the executive compensation program and amend the 2017 Stock Option and Incentive Plan were not approved. However, the selection of Wipfli LLP as the independent registered public accounting firm for 2025 was ratified.

Spark’s Take on ICCC Stock

According to Spark, TipRanks’ AI Analyst, ICCC is a Neutral.

Immucell’s overall score reflects strong sales growth and improvements in financial performance highlighted in the earnings call, alongside bullish technical indicators. However, challenges in valuation due to high P/E and profitability issues weigh down the score. The new CFO appointment is a positive strategic move, expected to enhance financial management.

To see Spark’s full report on ICCC stock, click here.

More about Immucell

Average Trading Volume: 24,994

Technical Sentiment Signal: Buy

Current Market Cap: $57.39M

See more insights into ICCC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1